Literature DB >> 33620731

Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety.

Casey W Williamson1, Michael V Sherer1, Dmitriy Zamarin2, Andrew B Sharabi1, Brandon A Dyer3, Loren K Mell1, Jyoti S Mayadev1.   

Abstract

Radiation therapy exerts a tumoricidal local effect as well as both local and systemic immunomodulation. Immune checkpoint blockade has become a widely used treatment modality across cancer types with a rapidly growing list of agents and US Food and Drug Administration-approved indications. Moreover, there may be synergy between radiation therapy and immune checkpoint blockade. Various strategies have been used, but the optimal sequencing of these therapies is unclear. In this review, the authors discuss the major mechanisms of available immune checkpoint inhibitors and explore the available preclinical and clinical evidence regarding treatment sequencing. They also review safety considerations and conclude with possible future directions.
© 2021 American Cancer Society.

Entities:  

Keywords:  cancer therapy sequencing; immune checkpoint blockade; immunotherapy; radiation therapy; radiosensitization

Mesh:

Substances:

Year:  2021        PMID: 33620731      PMCID: PMC9376883          DOI: 10.1002/cncr.33424

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.921


  70 in total

1.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

Authors:  Yoshiko Iwai; Seigo Terawaki; Tasuku Honjo
Journal:  Int Immunol       Date:  2004-12-20       Impact factor: 4.823

2.  Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.

Authors:  Penny Fang; Wen Jiang; Pamela Allen; Isabella Glitza; Nandita Guha; Patrick Hwu; Amol Ghia; Jack Phan; Anita Mahajan; Hussein Tawbi; Jing Li
Journal:  J Neurooncol       Date:  2017-05-12       Impact factor: 4.130

3.  Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Authors:  S Peters; E Felip; U Dafni; C Belka; M Guckenberger; A Irigoyen; E Nadal; A Becker; H Vees; M Pless; A Martinez-Marti; A Tufman; M Lambrecht; N Andratschke; A C Piguet; M Kassapian; H Roschitzki-Voser; M Rabaglio-Poretti; R A Stahel; J Vansteenkiste; D De Ruysscher
Journal:  Lung Cancer       Date:  2019-05-03       Impact factor: 5.705

Review 4.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

5.  A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.

Authors:  Shin Foong Ngiow; Arabella Young; Nicolas Jacquelot; Takahiro Yamazaki; David Enot; Laurence Zitvogel; Mark J Smyth
Journal:  Cancer Res       Date:  2015-07-24       Impact factor: 12.701

6.  Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

Authors:  Jizhong Liu; Abdelbasset Hamrouni; Darius Wolowiec; Valérie Coiteux; Kazimierz Kuliczkowski; Dominique Hetuin; Aurore Saudemont; Bruno Quesnel
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Authors:  Yansheng Hao; Bjoern Chapuy; Stefano Monti; Heather H Sun; Scott J Rodig; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

Review 9.  Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.

Authors:  Yifan Wang; Weiye Deng; Nan Li; Shinya Neri; Amrish Sharma; Wen Jiang; Steven H Lin
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

10.  B cells and tertiary lymphoid structures promote immunotherapy response.

Authors:  Beth A Helmink; Sangeetha M Reddy; Jianjun Gao; Shaojun Zhang; Rafet Basar; Rohit Thakur; Keren Yizhak; Moshe Sade-Feldman; Jorge Blando; Guangchun Han; Vancheswaran Gopalakrishnan; Yuanxin Xi; Hao Zhao; Rodabe N Amaria; Hussein A Tawbi; Alex P Cogdill; Wenbin Liu; Valerie S LeBleu; Fernanda G Kugeratski; Sapna Patel; Michael A Davies; Patrick Hwu; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Reetakshi Arora; Scott Woodman; Emily Z Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N Spencer; Elizabeth M Burton; Lauren E Haydu; Alexander J Lazar; Roberta Zapassodi; Courtney W Hudgens; Deborah A Ledesma; SuFey Ong; Michael Bailey; Sarah Warren; Disha Rao; Oscar Krijgsman; Elisa A Rozeman; Daniel Peeper; Christian U Blank; Ton N Schumacher; Lisa H Butterfield; Monika A Zelazowska; Kevin M McBride; Raghu Kalluri; James Allison; Florent Petitprez; Wolf Herman Fridman; Catherine Sautès-Fridman; Nir Hacohen; Katayoun Rezvani; Padmanee Sharma; Michael T Tetzlaff; Linghua Wang; Jennifer A Wargo
Journal:  Nature       Date:  2020-01-15       Impact factor: 69.504

View more
  5 in total

1.  In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma.

Authors:  Michael Zhang; Quan Zhou; Chinghsin Huang; Carmel T Chan; Wei Wu; Gordon Li; Michael Lim; Sanjiv S Gambhir; Heike E Daldrup-Link
Journal:  Mol Imaging Biol       Date:  2021-11-30       Impact factor: 3.484

Review 2.  Defining Immunogenic and Radioimmunogenic Tumors.

Authors:  Terry R Medler; Tiffany C Blair; Marka R Crittenden; Michael J Gough
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

3.  A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.

Authors:  Anifat A Elegbede; Amanda J Gibson; Andrea S Fung; Winson Y Cheung; Michelle L Dean; D Gwyn Bebb; Aliyah Pabani
Journal:  JTO Clin Res Rep       Date:  2021-10-28

4.  Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.

Authors:  Bo Zhang; Jinbo Yue; Xuetao Shi; Kai Cui; Lei Li; Chengsheng Zhang; Pengfei Sun; Jingtao Zhong; Zhongchao Li; Lei Zhao
Journal:  BMJ Open       Date:  2022-09-17       Impact factor: 3.006

Review 5.  Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.

Authors:  Janice L Farlow; J Chad Brenner; Yu L Lei; Steven B Chinn
Journal:  Oral Oncol       Date:  2021-07-01       Impact factor: 5.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.